CA2664935A1 - Compositions de traitement de l'hepatite c et procedes d'utilisation des compositions de traitement de l'hepatite c - Google Patents

Compositions de traitement de l'hepatite c et procedes d'utilisation des compositions de traitement de l'hepatite c Download PDF

Info

Publication number: CA2664935A1
Authority: CA; Canada
Prior art keywords: ibogaine; composition; noribogaine; tabernanthine; ibogamine
Prior art date: 2006-09-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002664935A

Other languages

English (en)

Inventor

Howard L. Lotsof

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Addiction Research Institute Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-26

Filing date

2006-09-26

Publication date

2008-04-03

2006-09-26 Application filed by Individual filed Critical Individual

2008-04-03 Publication of CA2664935A1 publication Critical patent/CA2664935A1/fr

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 48
238000000034 method Methods 0.000 title claims abstract description 38
208000006454 hepatitis Diseases 0.000 title description 5
231100000283 hepatitis Toxicity 0.000 title description 5
AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 claims abstract description 78
HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 claims abstract description 61
VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 claims abstract description 60
OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 claims abstract description 60
208000005176 Hepatitis C Diseases 0.000 claims abstract description 41
RAUCDOKTMDOIPF-UHFFFAOYSA-N hydroxyibogamine Natural products CCC1CC(C2)CC3C1N2CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-UHFFFAOYSA-N 0.000 claims abstract description 26
RAUCDOKTMDOIPF-RYRUWHOVSA-N noribogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-RYRUWHOVSA-N 0.000 claims abstract description 26
150000003839 salts Chemical class 0.000 claims abstract description 23
239000002207 metabolite Substances 0.000 claims abstract description 21
210000004185 liver Anatomy 0.000 claims abstract description 18
102000004190 Enzymes Human genes 0.000 claims abstract description 9
108090000790 Enzymes Proteins 0.000 claims abstract description 9
231100000252 nontoxic Toxicity 0.000 claims description 20
230000003000 nontoxic effect Effects 0.000 claims description 20
UCIDWKVIQZIKEK-NXWOVTFFSA-N Tabernanthine Chemical compound N1([C@@H]2[C@H]3C[C@@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC(OC)=CC=C12 UCIDWKVIQZIKEK-NXWOVTFFSA-N 0.000 claims description 18
LRLCVRYKAFDXKU-YGOSVGOTSA-N ibogamine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=CC=C12 LRLCVRYKAFDXKU-YGOSVGOTSA-N 0.000 claims description 18
UCIDWKVIQZIKEK-UHFFFAOYSA-N tabernanthine Natural products CCC1CC(C2)CC3C1N2CCC1=C3NC2=CC(OC)=CC=C12 UCIDWKVIQZIKEK-UHFFFAOYSA-N 0.000 claims description 18
102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 11
108010082126 Alanine transaminase Proteins 0.000 claims description 11
108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 11
102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 11
230000037396 body weight Effects 0.000 claims description 10
102000002260 Alkaline Phosphatase Human genes 0.000 claims description 6
108020004774 Alkaline Phosphatase Proteins 0.000 claims description 6
239000002775 capsule Substances 0.000 claims description 6
239000003826 tablet Substances 0.000 claims description 6
230000008961 swelling Effects 0.000 claims description 4
208000002193 Pain Diseases 0.000 claims description 3
230000036407 pain Effects 0.000 claims description 3
239000003182 parenteral nutrition solution Substances 0.000 claims description 3
239000000829 suppository Substances 0.000 claims description 3
102000004357 Transferases Human genes 0.000 claims description 2
108090000992 Transferases Proteins 0.000 claims description 2
239000011230 binding agent Substances 0.000 claims description 2
238000005516 engineering process Methods 0.000 claims description 2
230000008447 perception Effects 0.000 claims description 2
230000000144 pharmacologic effect Effects 0.000 claims description 2
239000000419 plant extract Substances 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 6
239000007788 liquid Substances 0.000 claims 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
229910019142 PO4 Inorganic materials 0.000 claims 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
229920002253 Tannate Polymers 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
239000000945 filler Substances 0.000 claims 1
229940060367 inert ingredients Drugs 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
239000010452 phosphate Substances 0.000 claims 1
229940095064 tartrate Drugs 0.000 claims 1
208000010710 hepatitis C virus infection Diseases 0.000 abstract description 6
230000000392 somatic effect Effects 0.000 abstract description 6
230000003612 virological effect Effects 0.000 abstract description 6
208000006154 Chronic hepatitis C Diseases 0.000 abstract description 2
WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 abstract 1
229930005303 indole alkaloid Natural products 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 description 17
241001246918 Tabernanthe iboga Species 0.000 description 12
229930013930 alkaloid Natural products 0.000 description 11
102000014150 Interferons Human genes 0.000 description 8
108010050904 Interferons Proteins 0.000 description 8
229940079322 interferon Drugs 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
238000002648 combination therapy Methods 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
241000700605 Viruses Species 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
208000011117 substance-related disease Diseases 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
206010013663 drug dependence Diseases 0.000 description 4
208000014674 injury Diseases 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
206010013654 Drug abuse Diseases 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
229960002069 diamorphine Drugs 0.000 description 3
238000009472 formulation Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000000463 material Substances 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
238000011160 research Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
102100024304 Protachykinin-1 Human genes 0.000 description 2
101800003906 Substance P Proteins 0.000 description 2
108020000999 Viral RNA Proteins 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000000284 extract Substances 0.000 description 2
-1 ibogaine Natural products 0.000 description 2
IKJFDJLQPHDRTD-ISYVNWANSA-N ibogaine hydrochloride Chemical compound Cl.N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 IKJFDJLQPHDRTD-ISYVNWANSA-N 0.000 description 2
231100001231 less toxic Toxicity 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical class [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
230000008733 trauma Effects 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
VLOWUTVRYMTRJO-HHNICDRHSA-N 12,13-dimethoxyibogamine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC(OC)=C(OC)C=C12 VLOWUTVRYMTRJO-HHNICDRHSA-N 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
208000029197 Amphetamine-Related disease Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
206010051779 Bone marrow toxicity Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000022497 Cocaine-Related disease Diseases 0.000 description 1
206010009895 Colitis ischaemic Diseases 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
101100438142 Drosophila melanogaster cac gene Proteins 0.000 description 1
206010014896 Enterocolitis haemorrhagic Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
241000710781 Flaviviridae Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
206010057852 Nicotine dependence Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033661 Pancytopenia Diseases 0.000 description 1
239000002202 Polyethylene glycol Chemical class 0.000 description 1
231100000766 Possible carcinogen Toxicity 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
208000037111 Retinal Hemorrhage Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical class [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Chemical class 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
241001122767 Theaceae Species 0.000 description 1
208000024799 Thyroid disease Diseases 0.000 description 1
208000025569 Tobacco Use disease Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
TUPNQYOVVIKOSC-COPFJBCUSA-K [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O TUPNQYOVVIKOSC-COPFJBCUSA-K 0.000 description 1
239000004015 abortifacient agent Substances 0.000 description 1
231100000641 abortifacient agent Toxicity 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000003797 alkaloid derivatives Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
201000002472 amphetamine abuse Diseases 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
231100000366 bone marrow toxicity Toxicity 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
201000001272 cocaine abuse Diseases 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
208000024389 cytopenia Diseases 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
201000008222 ischemic colitis Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
208000018769 loss of vision Diseases 0.000 description 1
231100000864 loss of vision Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
231100000707 mutagenic chemical Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
229920001223 polyethylene glycol Chemical class 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001337 psychedelic effect Effects 0.000 description 1
238000001671 psychotherapy Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
229940098467 rectal solution Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
230000004044 response Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Chemical class 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
239000000454 talc Chemical class 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000003512 tremorgenic effect Effects 0.000 description 1
239000013598 vector Substances 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
230000009265 virologic response Effects 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Virology (AREA)
Emergency Medicine (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002664935A 2006-09-26 2006-09-26 Compositions de traitement de l'hepatite c et procedes d'utilisation des compositions de traitement de l'hepatite c Abandoned CA2664935A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2006/037231 WO2008039179A1 (fr)	2006-09-26	2006-09-26	Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c

Publications (1)

Publication Number	Publication Date
CA2664935A1 true CA2664935A1 (fr)	2008-04-03

Family

ID=39230475

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002664935A Abandoned CA2664935A1 (fr)	2006-09-26	2006-09-26	Compositions de traitement de l'hepatite c et procedes d'utilisation des compositions de traitement de l'hepatite c

Country Status (4)

Country	Link
EP (1)	EP2083825A4 (fr)
CA (1)	CA2664935A1 (fr)
IL (1)	IL197804A0 (fr)
WO (1)	WO2008039179A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR201107537A2 (tr)	2011-08-01	2012-01-23	Tataroğlu Vedat	Hepatit c hastalığınınn iyileştirilmesi için bitkisel bir kompozisyon ve bu bitkisel kompozisyonun kullanım yöntemi.
EP2583680A3 (fr)	2011-10-21	2013-06-12	Abbvie Inc.	Traitement seul (PSI-7977) ou combinatoire dans l'utilisation pour le traitement du VHC
AU2013201406B2 (en)	2011-10-21	2014-10-02	Abbvie Ireland Unlimited Company	Methods for treating HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
WO2014010197A1 (fr) *	2012-07-11	2014-01-16	パナソニック株式会社	Composant électronique
AU2015225442A1 (en) *	2014-03-03	2016-10-20	Demerx, Inc.	Therapeutic uses of ibogaine and related compounds
US20150246055A1 (en) *	2014-03-03	2015-09-03	Demerx, Inc.	Methods for acute and long-term treatment of opioid and opioid-like drug addiction
US9561233B2 (en)	2014-03-13	2017-02-07	Demerx, Inc.	Use of ibogaine for the treatment of pain
US9592239B2 (en)	2014-09-12	2017-03-14	Demerx, Inc.	Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
WO2017189978A1 (fr)	2016-04-28	2017-11-02	Emory University	Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
US12459965B2 (en)	2017-10-09	2025-11-04	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
AU2020258086A1 (en)	2019-04-17	2021-11-11	Compass Pathfinder Limited	Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
JP2022550569A (ja)	2019-10-03	2022-12-02	スタートンセラピューティクス，インコーポレイティド	ドロナビノールの経皮送達
US12409131B2 (en)	2019-10-03	2025-09-09	Pike Therapeutics Usa, Inc.	Transdermal delivery of dronabinol
US12016829B2 (en)	2019-10-11	2024-06-25	Pike Therapeutics Inc.	Pharmaceutical composition and method for treating seizure disorders
MX2022004257A (es)	2019-10-11	2022-05-26	Pike Therapeutics Inc	Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
US12121617B2 (en)	2019-10-14	2024-10-22	Pike Therapeutics Inc.	Transdermal delivery of cannabidiol
MX2022004258A (es)	2019-10-14	2022-05-26	Pike Therapeutics Inc	Entrega transdermica de cannabidiol.
US12268699B2 (en)	2019-10-14	2025-04-08	Pike Therapeutics Inc.	Transdermal delivery of tetrahydrocannabinol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5152994A (en) *	1990-05-31	1992-10-06	Lotsof Howard S	Rapid method for interrupting or attenuating poly-drug dependency syndromes
AT408719B (de) *	2000-03-22	2002-02-25	Nowicky Wassili	Mittel zur behandlung von hepatitis c

2006
- 2006-09-26 EP EP06815317A patent/EP2083825A4/fr not_active Withdrawn
- 2006-09-26 CA CA002664935A patent/CA2664935A1/fr not_active Abandoned
- 2006-09-26 WO PCT/US2006/037231 patent/WO2008039179A1/fr not_active Ceased
2009
- 2009-03-25 IL IL197804A patent/IL197804A0/en unknown

Also Published As

Publication number	Publication date
IL197804A0 (en)	2009-12-24
WO2008039179A1 (fr)	2008-04-03
EP2083825A4 (fr)	2009-11-04
EP2083825A1 (fr)	2009-08-05

Publication	Publication Date	Title
CA2664935A1 (fr)	2008-04-03	Compositions de traitement de l'hepatite c et procedes d'utilisation des compositions de traitement de l'hepatite c
US20060229293A1 (en)	2006-10-12	Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
US20080096832A1 (en)	2008-04-24	Method for Improving the Pharmacokinetics of an NNRTI
WO2001062295A1 (fr)	2001-08-30	Medicaments contenant des ingredients actifs combines
CN116367834A (zh)	2023-06-30	包含衣壳蛋白抑制剂和核苷类似物的药物组合
JPH03170475A (ja)	1991-07-24	抑うつ症治療剤
CN108904484A (zh)	2018-11-30	一种没食子酸乙酯的用途
CN110325214A (zh)	2019-10-11	用于预防和治疗神经元损伤的低剂量药物组合
JP3885135B2 (ja)	2007-02-21	Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤
CN114272254A (zh)	2022-04-05	甘草次酸和芍药苷的组合在治疗肝损伤、肝纤维化中的应用
WO2019232740A1 (fr)	2019-12-12	Composition pharmaceutique destinée à prévenir le diabète et utilisation correspondante
JPH11508247A (ja)	1999-07-21	ウベニメクス及びウベニメクスを含む医薬組成物のウイルス性肝炎の治療薬としての用途
WO2009084732A1 (fr)	2009-07-09	Agent servant à soulager les effets secondaires néfastes d'une thérapie de combinaison interféron/ribavirine
JP7749545B6 (ja)	2025-11-14	Ｔｌｒ７作用薬を含む薬物の組み合わせ
JP2857388B1 (ja)	1999-02-17	アカメガシワ樹皮のエキスを有効成分とする肝機能改善剤、肝機能改善飲料、及び肝機能改善茶
CN1330373C (zh)	2007-08-08	含alfa－干扰素，阿地福韦和二脱氧氟硫代胞嘧啶的药物组合物
CN1238053C (zh)	2006-01-25	含alfa－干扰素，拉米夫定和阿地福韦酯的药包
CN119033794A (zh)	2024-11-29	胆酸和非诺贝特在流感病毒感染中的应用
CN119326894A (zh)	2025-01-21	Gsdme抑制剂用于制造预防和治疗化疗时外周神经损伤的药物的用途
CN118976012A (zh)	2024-11-19	一种gsdmd抑制剂预防化疗时外周神经损伤的用途
CN115181097A (zh)	2022-10-14	乙肝核心蛋白抑制剂
CN118976093A (zh)	2024-11-19	一种γ-谷氨酰半胱氨酸用于防止化疗药物引发的周围神经细胞损伤的用途
CN106619591A (zh)	2017-05-10	奥昔卡因在制备药物中的用途及药物组合物
CN114903991A (zh)	2022-08-16	Glp-1r受体激动剂在制备治疗肝病相关药物中的用途
CN115607560A (zh)	2023-01-17	用于治疗乙型肝炎的药物组合物及其制备方法

Legal Events

Date	Code	Title	Description
2011-09-26	FZDE	Discontinued